SCHEMBL333835

SCHEMBL333835

O=C(O)Cc1c(C(=O)O)c2cc(Oc3cccc(Cl)c3)ccc2n1-c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.47
USP14 P54578 1/20 0.46
MAPT P10636 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
ALDH1A1 P00352 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
HTT P42858 1/20 0.42
FFAR1 O14842 1/20 0.41
HIF1A Q16665 1/20 0.41
PTGES O14684 1/20 0.41
TP53 P04637 2/20 0.41
GAA P10253 1/20 0.40
GFER P55789 1/20 0.40
THRB P10828 2/20 0.39
AGTR1 P30556 1/20 0.39
FNTA P49354 1/20 0.39
FNTB P49356 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL334162 0.91 USP14 (0.52) KDM4EUSP14MAPTSMN1; SMN2ALDH1A1
SCHEMBL334342 0.90 USP14 (0.45) KDM4EUSP14FFAR1HIF1APTGES
SCHEMBL333497 0.89 USP14 (0.44) KDM4EUSP14MAPTFFAR1HIF1A
SCHEMBL333845 0.89 PPARG (0.42) KDM4EUSP14FFAR1HIF1APTGES
SCHEMBL503756 0.89 USP14 (0.45) KDM4EUSP14MAPTFFAR1HIF1A
SCHEMBL334064 0.88 USP14 (0.43) KDM4EUSP14MAPTSMN1; SMN2ALDH1A1
SCHEMBL333664 0.88 KDM4E (0.46) KDM4EUSP14MAPTSMN1; SMN2ALDH1A1
SCHEMBL1407282 0.87 PPARG (0.50) THRB
SCHEMBL4171314 0.87 PPARG (0.42) KDM4EUSP14PTGESTHRB
SCHEMBL334194 0.86 PPARG (0.45) KDM4EUSP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097623-B2 1-Aryl-or heteroaryl-3-aryl-or heteroarylindole-2-carboxylic acids or esters: e.g., 5-(4-tert-Butylphenyl)-1,3-bis(4-isopropoxyphenyl)-indole-2-carboxylic acid; inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C4 and/or 5-lipoxygenase-activating protein; analgesics BIOLIPOX AB (SE) 2012-01-17 US disclosed
EP-1841735-B1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2011-03-09 EP disclosed
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2009-03-19 US disclosed
CN-101142185-A Indoles useful in the treatment of inflammation BIOLIPOX AB (SE) 2008-03-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation IDO1, IDO2, AREG KDM4E 1104/4885USP14 3873/4885MAPT 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.